ePT--the Electronic Newsletter of Pharmaceutical Technology, Jul 28, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Jul 28, 2011
News
CDER Identifies Key Regulatory Science Needs and Strategies
By Angie Drakulich
FDA released this week a report from its Center for Drug Evaluation and Research (CDER) that identifies regulatory science needs that will guide CDER's strategic planning in the years ahead and allow it to fulfill its regulatory mission.
BMS to Acquire Amira for $325 Million
By Stephanie Sutton
Bristol-Myers Squibb has signed an agreement to acquire Amira Pharmaceuticals, a small-molecule company with a focus on treatments for inflammatory and fibrotic diseases, for $325 million.
WHO Predicts Flu-Vaccine Production Will Double by 2015
By Erik Greb
The global production of seasonal influenza vaccine will double to 1.7 billion doses by 2015, according to a World Health Organization presentation.
Foreign Scientists Welcome, Sort Of
By Amy Ritter
The age of globalized industry should result in fewer barriers between countries, but in practice it is rarely that straightforward, according to a report by ScienceInsider.
EMA Improves the Readability of Packaging Leaflets
By Stephanie Sutton
The European Medicines Agency has updated the template for package leaflets to make the information easier for patients to understand.
Week of July 25, 2011: AstraZeneca Receives FDA Approval for Brilinta; Sanofi Makes Several Senior Appointments; and More.
AstraZeneca Receives FDA Approval for Brilinta; Sanofi Makes Several Senior Appointments; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Click here